Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 14/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23194701 | 1.00 | ALOX5 (0.48) | ALOX5PSEN1MEN1KMT2APDE4A | |
| SCHEMBL23166880 | 1.00 | ALOX5 (0.48) | ALOX5PSEN1MEN1KMT2APDE4A | |
| SCHEMBL23166882 | 1.00 | ALOX5 (0.48) | ALOX5PSEN1MEN1KMT2APDE4A | |
| SCHEMBL23167035 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 | |
| SCHEMBL23166883 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 | |
| SCHEMBL20822122 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 | |
| SCHEMBL23166886 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 | |
| SCHEMBL23167156 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 | |
| SCHEMBL23167037 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 | |
| SCHEMBL29670788 | 0.94 | ALOX5 (0.58) | ALOX5PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400529-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4038076-A1 | CHINONE-, HYDROCHINOME- AND NAPHTHOCHINONE-ANALOGUES OF VATIQUIONE FOR TREATMENT OF MITOCHONDRIAL DISORDER DISEASES | Stealth BioTherapeutics Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114746430-A | Quinone-, hydroquinone-and naphthoquinone-analogues of vattinoquinone for the treatment of mitochondrial disorders | 康德生物医疗有限公司 | 2022-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400529-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | FH, COQ8A, TFAM | ALOX5 1622/4885PSEN1 285/4885MEN1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.